Combination of Ranibizumab and Targeted Laser Photocoagulation

Central Retinal Vein Occlusion With Macular Edema Clinical Trial

— CoRaLaII  

Official title:

Long-term Need of Ranibizumab Injections With or Without Early Targeted Peripheral Laser Photocoagulation for Treatment of Macular Edema Due to Central Retinal Vein Occlusion

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04444492
• Other study ID #: CoRaLaII
• Status: Recruiting
• Phase: Phase 3
• Start date: August 25, 2020
• Est. completion date: July 30, 2025

Study information

• Verified date: November 2023
• Source: University of Giessen
• Contact: Matus Rehak, Professor
• Phone: 0049 641 985 438 01
• Email: matus.rehak[@]uk-gm.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Intravitreal injections of Ranibizumab will be applied in all patients according to treatment guidelines. The experimental group will receive additional targeted laser photocoagulation of the peripheral areas of capillary non-perfusion (up to 4 laser treatments within 1st year of the study). Based on the long-term observation after CoRaLa I study an importantly shorter duration of treatment and a relevant reduction of the total number of re-injections in RL patients is expected.

Description:

Retinal vein occlusion (RVO) is the second most common retinal vascular disease leading to visual impairment. Main cause for visual impairment in CRVO (Central Retinal Vein Occlusion) is macular edema (ME) while neovascularization of the retina and/or the anterior segment is the most serious complication leading to vitreous hemorrhage, retinal detachment and neovascular glaucoma. In serious cases loss of vision is imminent. To date, no causal treatment has been proven to be effective in large trials. Intravitreal injections of drugs that inhibit the vascular endothelial growth factor (VEGF) and other inflammatory factors are the current treatments of choice for ME due to CRVO. Two different anti-VEGF drugs (ranibizumab and aflibercept), and a biodegradable dexamethasone implant are approved by the EMA (European Medicines Agency). Based on data from confirmatory studies anti-VEGF-drugs are recommended as a treatment of first choice in patients with RVO. All intravitreal drugs provide only a temporary effect with need for re-treatment for recurrences of ME. Mean number of ranibizumab application needed in CRVO patients was found to be 7.4 to 10.2 injections in 12 months. A significant number of CRVO patients require treatment over several years. Need for repetitive treatments and ophthalmic controls are a major burden for patients (and their relatives who are required for driving the patients to ophthalmologists) despite of only few adverse events and generally well-tolerated injections. Endophthalmitis is the most severe ocular complication which can be eye-sight-threatening. The more injections are administered, the higher is the cumulative risk of complications. Due to high costs (>1000 € per injection) treatment with repeated injections over years is of significant socio-economic importance, too. Therefore, treatments concepts which would lead to permanent reduction of ME and/or significantly reduce the number of re-injections over long-term periods are the major currently unmet need in patients with RVO. Until now, several studies evaluated the impact of the additional pan-retinal laser photocoagulation in patients undergoing the anti-VEGF-treatment for the ME due to retinal vein occlusions. However, most of the studies are limited by retrospective design, small number of evaluated patients or lack of the randomization. None of the available prospective randomized studies had sufficient power to finally clarify the benefit of the additional laser treatment. Therefore, there is an unmet need for a large randomized, prospective, multicentric trials. The proposed study will be the first sufficiently powered trial evaluating the long-term effect of targeted laser photocoagulation performed selectively (targeted) in peripheral areas of non-perfusion in combination with standard anti-VEGF treatment (ranibizumab injections) on the duration of the required intravitreal treatment over time period of 2 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 110
• Est. completion date: July 30, 2025
• Est. primary completion date: July 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of macular edema due to central retinal vein occlusion foveal thickness > 250 µm (measured by OCT)
• Age > 18 years
• Written informed consent of the patient
• BCVA score in the study eye between 24 letters (20/320) and 78 letters (20/25) measured in ETDRS chart
• History of CRVO no longer than 6 months
• Presence of capillary non-perfusion in peripheral retina larger than 5 disc areas documented in ultra wide-field fluorescein angiography
• Ability and willingness to attend all scheduled visits and assessments

Exclusion Criteria:

• CRVO with ischemic maculopathy defined as diameter of the foveolar avascular zone larger than 2 optic disc diameters
• Macular edema due to another etiology than retinal vein occlusion (e.g. diabetic maculopathy, uveitis, age related macular degeneration, Irvine-Gass syndrome)
• History of idiopathic central serous chorioretinopathy
• Presence of vitreoretinal interface disease (e.g. vitreomacular traction, epiretinal membrane), either on clinical examination or in OCT
• An eye that, in the investigator's opinion, would not benefit from resolution of macular edema, such as eyes with foveal atrophy, dense pigmentary changes, or dense subfoveal hard exudates
• Aphakia in the study eye
• Scatter laser photocoagulation or macular photocoagulation in the study eye prior to study entry
• Intraocular or periocular injection of steroids in the study eye prior to study entry
• Previous use of an anti-VEGF drug in the study eye
• Cataract surgery or any other intraocular surgery in the study eye within 3 months prior to study entry
• Uncontrolled glaucoma (defined as intraocular pressure = 30 mm Hg despite treatment with maximal anti-glaucoma medications)
• History of stroke, myocardial infarction, transient ischemic attacks within 3 months prior to the study
• Pregnancy (positive urine pregnancy test) or lactation
• The presence of active malignancy, including lymphoproliferative disorders.
• History of allergy to fluorescein or any component of the ranibizumab formulation
• Active intraocular infection
• Participation in another simultaneous interventional medical investigation or trial
• Women with child bearing potency without effective contraception (i. e. implants, injectables, combined oral contraceptives, some IUDs or vasectomised partner) during the conduct of the trial.

Related Conditions & MeSH terms

• Central Retinal Vein Occlusion With Macular Edema
• Macular Edema
• Retinal Vein Occlusion

Intervention

Drug:
• Ranibizumab Injection
initial three injections of Ranibizumab - afterwards pro re nata monthly

Device:
• Laser photocoagulation
Areas of capillary non-perfusion will be treated with photocoagulation upto 4 times

Locations

Country	Name	City	State
Germany	Universitätsklinikum Carl Gustav Carus Dresden Klinik und Polyklinik für Augenheilkunde	Dresden
Germany	Internationale Innovative Ophthalmochirurgie GbR, Klinik für Augenchirurgie	Düsseldorf
Germany	Universitätsklinikum Klinik für Augenheilkunde Freiburg	Freiburg
Germany	Universitätsklinikum Gießen, Klinik und Poliklinik für Augenheilkunde	Gießen
Germany	Hannover MHH Universitätsklinik für Augenheilkunde	Hannover
Germany	University Hospital of Leipzig Department of Ophthalmology	Leipzig
Germany	Klinikum der Stadt Ludwigshafen Augenklinik	Ludwigshafen
Germany	Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg Klinik für Augenheilkunde	Marburg
Germany	Ludwig-Maximilians-Universität München, Augenklinik	München
Germany	Augenzentrum am St. Franziskus-Hospital Münster	Münster
Germany	Universitätsklinikum Klinik für Augenheilkunde	Münster
Germany	Universitätsklinikum Tübingen, Department für Augenheilkunde	Tübingen
Germany	Universitätsklinikum Ulm, Klinik für Augenheilkunde	Ulm
Germany	Augen-OP-Zentrum Zschopau, Praxis für Augenheilkunde	Zschopau

Sponsors (2)

Lead Sponsor	Collaborator
University of Giessen	University of Leipzig

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Development of neovascularization(s)	Proportion of subjects developing neovascularization(s) of retina, optic disc, and/or in anterior segment over the total period of observation.	Month 24
Other	The area of non-perfusion	The area of non-perfusion (assessed by FA) will be quantified as sum of all areas identified	Month 24
Other	Vessel density	Assessed by OCT-angiography, will be quantified by a metric measure with the range [0;1]	Month 24
Other	Potential visual field loss	The change between the two timepoints (Months 4 and 24) per arm will be used to characterize the both groups and be compared between treatment arms.	Month 4 and Month 24
Other	The number of laser treatments and the laser spots given in the experimental group (RL-arm).	The number of visits with applied laser treatment and the laser spots applied in the experimental group (RL-arm) will be counted for descriptive reasons and be compared between treatment arms.	Month 24
Other	Health-related quality of life (QoL): Visual Function Questionnaire VFQ25	Measured by the Visual Function Questionnaire VFQ25	Baseline, Month 12 and Month 24
Other	Areal of foveal avascular zone	Area of the foveal avascular zone (FAZ, assessed by OCT-angiography, will be quantified in [mmm²])	Month 24
Primary	Efficacy endpoint is the time to treatment success	Time from randomisation until the date of last criteria-based intravitreal injection in case that thereafter a treatment-free period for (at least) 6 months was observed.	up-to 29 months
Secondary	Best corrected visual acuity (BCVA)	Best corrected visual acuity (BCVA) in number of ETDRS letters (Early Treatment of Diabetes Retinopathy Study) per visit	Month 29
Secondary	Central subfield thickness (CST)	Central subfield thickness (CST) measured by OCT per visit	Month 29
Secondary	Number of ranibizumab injections	Number of ranibizumab injections required until treatment success and up to the end of Observation.	Month 29